Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dynamic Medical Technologies Inc. (4138.TWO)
New Taipei City, TW
Dynamic Medical Technologies Inc., encompassing its various subsidiaries, operates within the aesthetic industry throughout Taiwan and Hong Kong. The company's primary focus involves the commercialization and upkeep of cosmetic laser and light-based equipment. Its extensive product range, which it both distributes and sells, includes specialized aesthetic medical instruments, body sculpting technologies, injectable dermal fillers, and high-grade cosmeceuticals, alongside a diverse selection of beauty treatment and cosmetic items. Additionally, Dynamic Medical Technologies delivers professional services such as training for aestheticians and consultation for clinical operational efficiency. The company is organized into distinct segments: Dynamic, Hong Kong Dynamic, Excelsior Beauty, and CYJ. Established in 1992, its main operational hub is situated in New Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | -1.75% | -9.64% | -13.50% | -20.44% | -15.95% | -32.03% | -37.35% | +26.12% | +2.04% | +12.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-11.8% Q1'26: -2.4% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-32.8% Q1'26: -26.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+18.7% ★ Q1'26: -13.7% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+13.7% ★ Q1'26: +10.0% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+15.7% ★ Q1'26: +12.1% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+29.5% Q1'26: +15.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.20× ★ Q1'26: 1.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 58.8K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chih-Hao Chiang | CFO & Chief Corporate Governance Officer | — | male |
| Kuo-Long Wu | GM & Representative Director | — | male |
| Zhihao Jiang | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4138.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
